Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN
RESEARCH TOOLSreports
Holding DAWN?
Track your performance easily
DAWN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.13 - $18.07
Previous CloseN/A
Volume175.11K
Average Volume (3M)1.11M
Market Cap
$1.13B
Enterprise Value$794.58M
Total Cash (Recent Filing)$27.33M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Mar 10, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.01
Shares Outstanding100,846,290
10 Day Avg. Volume1,306,702
30 Day Avg. Volume1,105,993
Standard Deviation0.32
R-Squared0.05
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)11.74
Price to Cash Flow (P/CF)5.90
P/FCF Ratio6.00
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue7.79
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.80
Forecast
1Y Price Target
$34.33Price Target Upside176.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Day One Biopharmaceuticals News
PremiumCompany Announcements
Day One Biopharmaceuticals Reports 2024 Financial Results
PremiumCompany Announcements
Day One Biopharmaceuticals Announces Leadership Transition
Bulls Say, Bears Say
Bulls Say
Financial PerformanceOjemda 4Q sales were approximately 11% above consensus estimates, indicating strong performance.
Market AcceptanceAll Tier 1 accounts have prescribed Ojemda, indicating strong initial acceptance in the market.
Pipeline GrowthThe company expanded its pipeline with a new asset, DAY301, targeting PTK7 in solid tumors, indicating potential future growth.
Bears Say
Clinical TrialsNew adverse events could lead to disruption in trial progress, affecting the company's future prospects.
Market AdoptionIncreased treatment discontinuation rates could lead to limited market adoption post approval.
Safety ConcernsPfizer and AbbVie discontinued development of a similar anti-PTK7 ADC due to toxicity issues, which may be a concern for DAY301.
---
Ownership Overview
17.68% Insiders
20.52% Mutual Funds
0.19% Other Institutional Investors
50.39% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DAWN FAQ
What was Day One Biopharmaceuticals’s price range in the past 12 months?
Day One Biopharmaceuticals lowest stock price was $11.13 and its highest was $18.07 in the past 12 months.
What is Day One Biopharmaceuticals’s market cap?
Day One Biopharmaceuticals’s market cap is $1.13B.
When is Day One Biopharmaceuticals’s upcoming earnings report date?
Day One Biopharmaceuticals’s upcoming earnings report date is Mar 10, 2025 which is in 51 days.
How were Day One Biopharmaceuticals’s earnings last quarter?
Day One Biopharmaceuticals released its earnings results on Oct 30, 2024. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of -$0.316 by $0.696.
Is Day One Biopharmaceuticals overvalued?
According to Wall Street analysts Day One Biopharmaceuticals’s price is currently Undervalued.
Does Day One Biopharmaceuticals pay dividends?
Day One Biopharmaceuticals does not currently pay dividends.
What is Day One Biopharmaceuticals’s EPS estimate?
Day One Biopharmaceuticals’s EPS estimate is -0.37.
How many shares outstanding does Day One Biopharmaceuticals have?
Day One Biopharmaceuticals has 100,846,290 shares outstanding.
What happened to Day One Biopharmaceuticals’s price movement after its last earnings report?
Day One Biopharmaceuticals reported an EPS of $0.38 in its last earnings report, beating expectations of -$0.316. Following the earnings report the stock price went up 1.728%.
Which hedge fund is a major shareholder of Day One Biopharmaceuticals?
Currently, no hedge funds are holding shares in DAWN
---
Day One Biopharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.33 (176.85% Upside)
$34.33 (176.85% Upside)
Blogger Sentiment
Bullish
DAWN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 3.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.98%
12-Months-Change
Fundamentals
Return on Equity
-17.84%
Trailing 12-Months
Asset Growth
45.06%
Trailing 12-Months
Company Description
Day One Biopharmaceuticals
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
---
DAWN Company Deck
---
DAWN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong positive tone with significant revenue growth from the successful launch of OJEMDA, substantial financial strength, and progress in pipeline expansion. However, increased operating expenses and expected challenges in market penetration were noted.Read More>---
DAWN Stock 12 Month Forecast
Average Price Target
$34.33
▲(176.85% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Fulcrum Therapeutics
―
Blueprint Medicines
―
Syros Pharmaceuticals
―
Crinetics Pharmaceuticals
―
Foghorn Therapeutics
―
Best Analysts Covering DAWN
1 Year
1 Year Success Rate
5/12 ratings generated profit
1 Year Average Return
+3.17%
reiterated a buy rating 6 months ago
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of +3.17% per trade.
---